Dr. Jay Bhattacharya's announcment can be viewed here: https://www.facebook.com/reel/844158475071307
FDA Leadership Profiles can be found here:
https://www.fda.gov/about-fda/fda-organization/fda-leadership-profiles
Email addresses for these officials were obtained here:
https://directory.psc.gov/employee.htm
Email to Jay Bhattacharya, M.D., Ph.D. Director of the National Institutes of Health:
---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: "jayanta.bhattacharya@nih.hhs.gov" <jayanta.bhattacharya@nih.hhs.gov>
Cc: "Sara.Brenner@fda.hhs.gov" <Sara.Brenner@fda.hhs.gov>, "Commissioner_Writein@fda.gov" <Commissioner_Writein@fda.gov>, "sean.keveney@hhs.gov" <sean.keveney@hhs.gov>, "Steven.Kozlowski@fda.hhs.gov" <Steven.Kozlowski@fda.hhs.gov>, "Jim.Traficant@fda.hhs.gov" <Jim.Traficant@fda.hhs.gov>, "Caleb.Michaud@fda.hhs.gov" <Caleb.Michaud@fda.hhs.gov>, "Lowell.Zeta@fda.hhs.gov" <Lowell.Zeta@fda.hhs.gov>
Date: 02/06/2026 12:56 PM EST
Subject: Director Dr. Bhattacharya: "At HHS we are absolutely committed to making sure we do gold-standard science to address your condition.”
National Institutes of Health (NIH) Director Dr. Bhattacharya: “The idea that Lyme is an intractable condition, that patients are just making things up — those days are long gone. At HHS we are absolutely committed to making sure we do gold-standard science to address your condition.”
Jay Bhattacharya, M.D., Ph.D.
Director of the National Institutes of Health
Dear Dr. Bhattacharya,
You have the correct stance on the issue but before we’ll see progress, individuals within HHS who have participated in the deception must go.
Let me explain…
The following is a summary of how far our public health officials will go for the sake of a vaccine when a chronic/relapsing seronegative infection does not fit the vaccine model. Suppressing evidence of antibiotic resistance is not collaboration, it is collusion.
The rush to create that vaccine early in the discovery phase of the outbreak led to the deliberate mishandling of the disease.
Below is an email sent to Adriana Marques, M.D. (NIH Lyme Disease Studies Unit) who refuses to respond to any inquiries questioning her viewpoint/authority. Marques is just one of many at HHS who must go if we are to see a resolution to this travesty.
Respectfully Submitted,
Carl Tuttle
Independent Researcher
Hudson, NH
Letter to the Editor of the BMJ published June 2020 (please read!)
https://www.bmj.com/content/369/bmj.m1041/rr-1
Cc: Sara Brenner M.D., M.P.H. Principal Deputy Commissioner FDA
Sean Keveney J.D. Chief Counsel
Steven Kozlowski, M.D. Chief Scientist
Jim Traficant, Chief of Staff
Caleb Michaud, Acting Associate Commissioner for External Affairs
Lowell M. Zeta, J.D., Deputy Commissioner for Strategic Initiatives
2024 Email sent to Adriana Marques, M.D. NIH Lyme Disease Studies Unit:
---------- Original Message ----------
From: CARL TUTTLE <runagain@comcast.net>
To: amarques@niaid.nih.gov
Cc: osmith@aaas.org, mnorton@aaas.org, ccharneski@aaas.org, cmalo@aaas.org, bberry@aaas.org, dhallberg@aaas.org, dneuhofer@aaas.org, mogle@aaas.org
Date: 11/14/2024 9:54 AM EST
Subject: Symptoms after Lyme disease: What’s past is prologue
SCIENCE TRANSLATIONAL MEDICINE
13 Nov 2024
Symptoms after Lyme disease: What’s past is prologue
ADRIANA MARQUES
https://www.science.org/doi/10.1126/scitranslmed.ado2103
“There have been five randomized, placebo-controlled, double-blind clinical trials addressing the question of whether additional antibiotic treatment benefits patients with PTLDS or symptoms attributed to Lyme disease.”
“The results of these trials showed that prolonged antibiotic treatment had no lasting benefit while having potential serious risks.”
Adriana Marques, M.D.
Lyme Disease Studies Unit
NIH Main Campus, Bethesda, MD
Dr. Marques,
For the record there are many infections requiring long-term antibiotics so why Klempner stopped his NIH funded antibiotic treatment trials for Lyme after “12 weeks” and then claimed no benefit makes absolutely no sense whatsoever:
From the following peer-reviewed publication:
Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease
https://www.dovepress.com/benefit-of-intravenous-antibiotic-therapy-in-patients-referred-for-tre-peer-reviewed-fulltext-article-IJGM
Infections requiring long-term antibiotics:
[https://www.dropbox.com/scl/fi/ali58e4tit6f5w6vnkrsw/Infections-requiring-long-term-antibiotics.png?rlkey=yqq4hrsgwmjjelzwjphmfb1cf&dl=0]
In 1991 the Lyme disease organism, Borrelia burgdorferi, was grown from the cerebrospinal fluid of Lyme patient Vicki Logan at the Centers for Disease Control in Fort Collins, Colorado despite prior treatment with intravenous antibiotics. The patient died when the insurer refused additional IV antibiotics. Here is a copy of Logan’s CDC positive culture report for your review.
(Vicki Logan’s Chronic Lyme Autopsy results Page #1, 2, 3, 4, 5, 6, 7)
There are 700 peer-reviewed publications referencing persistent infection and in a 2018 study all patients were culture positive even after multiple years on antibiotics so there was no relief from current antimicrobials. Some of these patients had taken as many as eleven different types of antibiotics.
Thirty-four years ago Dr. Allen Steere identified chronic Lyme disease which should have set off a red flag prompting an immediate search for better antimicrobials but then did a 180° as he became principal investigator (PI) of the Phase 3 clinical trial for the first Lyme disease vaccine. So all the eggs were put into the vaccine basket while a campaign was orchestrated to discredit the sick and disabled patient population along with the courageous clinicians attempting to help these patients. Apparently, a chronic relapsing seronegative disease did not fit the business model of patent royalties, vaccine development and pharmaceutical profits.
Here is Dr. Steere’s 1990 publication summary for your review:
The New England Journal of Medicine
Published November 22, 1990
Chronic neurologic manifestations of Lyme disease
https://www.nejm.org/doi/full/10.1056/NEJM199011223232102
The chart below summarizes Lyme research funded by the NIH and only 2.5% has been allocated for treatment:
[https://www.dropbox.com/scl/fi/qzgpm35h33i3r6yjrovve/Lyme-research-NIH.png?rlkey=eg0pqg2ahdpszqfvzt8slro3q&dl=0]
Question:
Is there a reason why these facts/references/lab reports are missing from your viewpoint published in Science Translational Medicine?
A response to this inquiry is requested.
Carl Tuttle
Independent Researcher
Hudson, NH USA
Cc: Orla M. Smith, Ph.D. Editor, Science Translational Medicine
Editorial Staff
Melissa Norton, M.D.
Catherine A. Charneski, Ph.D.
Courtney S. Malo, Ph.D.
Brandon Berry, Ph.D.
Dorothy L. Hallberg, Ph.D.
Daniela Neuhofer, Ph.D.
Molly Ogle, Ph.D.